Athersys stem cell therapy wins scientists’ plaudits

MedCity News logo

By Mary Vanac

Doctors and researchers at the Athersys Inc. (NSDQ:ATHX) investor meeting in New York City expressed hope that the company’s stem cell therapy — MultiStem — could raise the ceiling on care for heart attack, stroke and some cancer patients, among others.

Biopharmaceutical company Athersys invited nearly a dozen stem cell experts — including Ruth McKernan, head of Pfizer Regenerative Medicine, with which Athersys is working on a therapy for inflammatory bowel disease — to its annual investor day May 15.

Of course, the experts had good things to say about MultiStem, the off-the-shelf stem cell product on which Athersys is doing clinical trials as a treatment for heart attack, stroke and bone marrow transplant patients.

“We and a growing number of others believe that MultiStem represents a significant advance in the field of regenerative medicine,” chairman and CEO Gil Van Bokkelen said. That’s because “it’s a drug-like stem cell therapy that can be manufactured on an industrial scale, it can be administered like Type O blood, it exhibits a consistent safety profile and it can provide multiple therapeutic benefits,” Van Bokkelen said.

One of the differences between MultiStem and competing therapies is the Athersys cells are scalable.

“Unlike traditional bone marrow or hematopoietic stem cell transplants that require a single donor for each patient, we have the ability to produce up to millions of doses of material from a single donor,” Van Bokkelen said. “This enables us to manufacture a clinical-grade product in a reproducible and consistent manner.”

In the body, MultiStem can promote multiple factors that protect tissue, promote tissue healing and repair and reduce inflammation in several ways. Athersys, which is conducting a Phase I trial of MultiStem to treat heart attack patients, is finding evidence that its stem cells also could treat peripheral vascular disease.

“MultiStem provides us with tremendous breadth, in terms of development opportunities,” Van Bokkelen said. “Through our broad research and network of collaborations with leading research labs and clinical experts, we’re generating a deep knowledge about the biology of MultiStem and its therapeutic potential across a range of disease areas. This allows us to explore future development opportunities in areas of significant clinical need.”

Those collaborations also have enabled Athersys to spread development costs among many institutions and to run a lean headquarters in Cleveland.

As a company, Athersys has spent a lot of time building an intellectual property portfolio to protect and extend its research and manufacturing capabilities.

“That’s a valuable asset that allows us to drive these platforms forward … in a way that allows us to protect the interests of our shareholders,” Van Bokkelen said.

Experts at the Athersys investor day painted a bigger picture of MultiStem’s potential — and the potential of other stem cell therapies — to raise the ceiling above current clinical practices and results.

“We’ve hit the ceiling” in treating heart attack patients, Dr. Warren Sherman, an interventional cardiologist and director of stem cell research and regenerative medicine at the Center for Interventional Vascular Therapy at Columbia University Medical Center in New York, told meeting participants. “There’s not much more we can do once the patients come to the emergency room.”

But what if we can undo the damage that’s been done?

“Repair mechanisms are our best hope for attempting to reverse what has gone on,” Sherman said. “There is a profound unmet need” among patients for regenerative therapies.

Athersys and its experts released some new information about the company’s trials of MultiStem for neurological damage:

  • Preclinical information recently published in the Journal of Experimental Stroke & Translational Medicine shows that MultiStem helps patients several days after stroke. Current standard-of-care requires patients to be treated within four hours of a stroke.
  • New preclinical data demonstrated MultiStem works by significantly reducing both inflammation and death of neurons in the brain following a stroke.
  • New data and preclinical research show MultiStem preserves the blood-brain barrier after traumatic brain injury and results in expression of anti-inflammatory proteins.
  • New preclinical research shows MultiStem can inhibit and reverse the “dieback” of neural cells following spinal cord injury.

“I began working with MultiStem several years ago because I was excited by the possibility of an off-the-shelf, non-immunogenic, intravenous stem cell therapy that could potentially ameliorate the effects of spinal cord injury,” Dr. Jerry Silver, neuroscience professor at Case Western Reserve University and adjunct professor of neurosurgery at the Cleveland Clinic, in an Athersys press release about the investor day.

“My research experience with these cells is that they are, indeed, fascinating. I have seen remarkable effects with MultiStem in preventing axonal dieback and promoting axonal sprouting — the most impressive impact of any potential therapy in my 30 years of research,” Silver said. “More studies are needed to determine the full functional benefits, but the results we’ve seen so far are extremely promising.”

RSS From Medical Design & Outsourcing

  • GlobTek presents its latest level VI AC/DC adapter and connverter
    T-43086-WWVV-X.X-Q Model is an addition to GlobTek’s Level VI compliant GT-43086 family and represents GlobTek’s 6 Watt wall plug-in series of AC/DC adapters (power supplies and chargers) with International Interchangeable blades. GlobTek’s changeable input blade system with individual field replaceable input plugs, including: North America and Japan NEMA 1-15P, Australian, UK BS 1363, European CEE […]
  • Sanmina’s familiarity with FDA gets skin treatment product to market fast
    The medical market for cosmetic devices is booming. However, quickly launching new products to meet demand is becoming more challenging because device manufactures face increased regulatory scrutiny. To help meet regulatory requirements, aesthetic and other medical-device OEMs are partnering with electronics manufacturing services (EMS) companies that also offer expertise with the FDA filings necessary to […]
  • Fluid connectors and quick disconnects for IVD equipment from CPC
    Colder Products Company (CPC) offers thousands of tubing connectors, quick disconnects and fittings for smart fluid handling in IVD and analytical equipment. Non-spill connectors speed testing throughput by eliminating drips, preventing air inclusion and increasing operator safety. Panel mount connectors can be added to existing equipment or bottle caps to provide secure, leak-free connections. Puncture […]
  • 310 Watt desktop medical power supply meets efficiency level VI requirements
    Power Partners releases a new 310 Watt medical grade desktop power supply from their PEAMD Series of AC and DC adapters. The 310 Watt unit is packed for ideal performance inside a compact case measuring 7.8 x 4 x 2 in. with a weight of only 3 lbs. The PEAMD310 Series is approved to the latest […]
  • Saelig introduces Multiple Instrument System MIS4 universal test system
    Saelig Company has introduced the ABI Electronics’ Multiple Instrument Station MIS4, an all-in-one testing tool that provides all commonly required test instruments in one compact programmable hardware module, mounted in a compact case or installed in a PC-drive bay. Controlled by ABI’s sophisticated SYSTEM 8 Ultimate PC software with a simple yet programmable operator interface, […]
  • AssurX announces document management software update for small to mid-size companies in FDA regulated industries
    AssurX, an enterprise quality management, risk and regulatory compliance solution provider, announces the release of the latest update to their AssurX document management software. The document management solution provides a cost-effective solution for small to medium sized companies faced with streamlined operations and is fully compliant for FDA regulated industries. Ideal solution for small to […]
  • Saelig presents new Amplicon Impact-R 1100F series computer
    Saelig Company announces the Amplicon Impact-R 1100F series, a fanless system powered by the Intel ATOM D2550 processor. Configured with a high performance 2.5 in. MLC Solid State Drive (SSD), the Impact-R 1100F series is a silent controller system. With options for multiple serial communication ports, the Impact-R 1100F can offer up seven DB9 connections […]
  • Gerresheimer to acquire Centor
    Gerresheimer AG, a partner to the global pharmacy and healthcare industry, will further extend its pharmaceutical packaging business with the acquisition of Centor. Gerresheimer has reached an agreement with Nemera Development S.A. to acquire 100% of the share capital of Centor US Holding. “Centor is the highly profitable market leader for plastic vials and closures in […]
  • Methods Machine Tools presents the new Nakamura-Tome NTRX-300
    Methods Machine Tools, a developer of precision machine tools and automation, has introduced the new Nakamura-Tome NTRX-300, a multitasking turning center featuring complete parts machining in one operation, with a built-in load and unload automation system and advanced operator recognition management software. The NTRX-300 features true opposing twin spindles: an 8 in. A2-6 25 HP or […]
  • MSC Apex Diamond Python and Smart Midsurface speeds modeling to validation
    MSC Software announced a new release of MSC Apex, the company’s award-winning next generation Computer Aided Engineering (CAE) platform. The MSC Apex Diamond Python release introduces: · The fourth release of MSC Apex Modeler is a CAE Specific direct modeling and meshing solution that streamlines CAD clean-up, simplification and meshing workflow. New in this release is […]
  • Quality Metrics: FDA’s plan for a key set of measurements to help ensure manufacturers are producing quality medications
    Editor’s Note: This article is written by Ashley Boam and Mary Malarkey from the “FDA Voice” blog. Boam is an FDA’s acting Director of the Office of Policy for Pharmaceutical Quality, the Office of Pharmaceutical Quality and the Center for Drug Evaluation and Research. Malarkey is an FDA’s Director if the Office of Compliance and Biologics Quality […]

Leave a Reply